National Marrow Donor Program Long-Term Donor Follow-Up
NCT ID: NCT01362179
Last Updated: 2020-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21974 participants
OBSERVATIONAL
2010-10-31
2020-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
NCT03000244
Graft-versus-host Disease Associated Myelosuppression
NCT02829216
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
NCT04528355
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
NCT00001623
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
NCT00106925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
unstimulated BM donors
Observational (non-interventional) study.
No interventions assigned to this group
filgrastim-mobilized PBSC donors
Observational (non-interventional) study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Unrelated donor who received at least one injection of filgrastim or more, but did not donate filgrastim-mobilized PBSC between July 1, 1999 and approximately five years post study activation.
3. Donation was managed by a U.S. NMDP donor center.
4. Signed informed consent for participation in this long-term donor follow-up study. Concurrent enrollment on other studies is permitted.
Exclusion Criteria
2. Donation was managed by a non-U.S. donor center.
3. Donor is unable to verbally communicate in any of the following languages: English, Spanish, Mandarin Chinese, Cantonese Chinese, Vietnamese, Korean, or Portuguese.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Marrow Donor Program
OTHER
Center for International Blood and Marrow Transplant Research
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John P Miller, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Marrow Donor Program
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
National Marrow Donor Program Northern California & Northwest District
Oakland, California, United States
National Marrow Donor Program Southern California & Southwest District
Santa Ana, California, United States
Colorado Marrow Donor Program
Denver, Colorado, United States
OneBlood
Fort Lauderdale, Florida, United States
Hawaii Bone Marrow Donor Registry
Honolulu, Hawaii, United States
LifeSource
Glenview, Illinois, United States
Rock River Valley Blood Center
Rockford, Illinois, United States
Indiana Blood Center
Indianapolis, Indiana, United States
National Marrow Donor Program Southcentral District, Heart of America
Leawood, Kansas, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Michigan Blood
Grand Rapids, Michigan, United States
The HLA Registry
Oradell, New Jersey, United States
New York Blood Center
Brooklyn, New York, United States
DKMS Americas
New York, New York, United States
National Marrow Donor Program Southeast District
Charlotte, North Carolina, United States
National Marrow Donor Program Northcentral District
Cleveland, Ohio, United States
Oklahoma Blood Institute
Oklahoma City, Oklahoma, United States
National Marrow Donor Program Northeast District
Philadelphia, Pennsylvania, United States
Rhode Island Blood Center
Providence, Rhode Island, United States
Blood Assurance, Inc.
Chattanooga, Tennessee, United States
Cooperative Appalachian Marrow Program Medic Regional Blood Center
Knoxville, Tennessee, United States
Baylor Research Institute
Dallas, Texas, United States
Cook Children's
El Paso, Texas, United States
Gulf Coast Regional Blood Center
Houston, Texas, United States
South Texas Blood and Tissue Center
San Antonio, Texas, United States
Scott & White Clinic
Temple, Texas, United States
Community Blood Center, Inc.
Appleton, Wisconsin, United States
National Marrow Donor Program at Puerto Rico
Guaynabo, PR, Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LTDFU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.